News and Trends 24 Aug 2022 Amgen announces top-line results from biosimilar phase 3 study Amgen has announced positive top-line results from its DAHLIA study. This was a randomized, double-blind, active-controlled, two-period crossover phase 3 study evaluating the efficacy and safety of ABP 959, a biosimilar candidate to SOLIRIS (eculizumab), compared with SOLIRIS in adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Amgen said the study met its primary endpoints, demonstrating […] August 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Northwest Biotherapeutics’ pediatric investigation plan approved by MHRA Northwest Biotherapeutics, a biotech company developing DCVax personalized immune therapies for solid tumor cancers, has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its pediatric investigation plan (PIP). The development, regulatory review and regulatory approval of a PIP is a pre-requisite for application for approval of a new medicine for […] August 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Freedom Biosciences exits stealth with $10.5M financing to develop mental health treatments Freedom Biosciences, a U.S. clinical-stage biotech platform developing ketamine and psychedelic therapeutics, today emerged from stealth with $10.5 million in seed financing. MBX Capital led the round and was joined by PsyMed Ventures, Village Global and The Yale Startup, among others. The new financing will help the company advance its current lead ketamine program as […] August 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Novel nanotechnology ‘supercharges’ immune system molecules to fight cancer Researchers from Cytimmune Sciences, a clinical-stage biotech company, have presented new data on the company’s novel cancer nanomedicines. The presentation took place at the Cytokine Drug Development Conference held in Boston, Massachusetts, late last month. David Oarr, Cytimmune’s president, participated in the event’s opening panel to discuss the current clinical status and future anticipated progress […] August 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 23 Aug 2022 Five industrial biotech companies making Japan more sustainable Japan has big plans to lead the world’s push to become more sustainable. Here are five local sustainable tech companies that could help it meet this mission. Japan is best known for its well-developed technology and manufacturing firms. The nation also hosts a thriving biotechnology sector, with players across sectors including healthcare and industrial biotechnology. […] August 23, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 BioInnovation Institute launches new program and takes on four companies The BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating life science research, says four companies have joined its new Venture House program. Formerly known as Creation House, the new Venture House program consists of the same 18-month long program with a risk-free convertible loan of €1.3 million ($1.3 million). […] August 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Parkinson’s Foundation and Parkinson’s UK partner to drive drug development The Parkinson’s Foundation and Parkinson’s UK, which funds research and provides support for people with Parkinson’s disease (PD), have announced a new international strategic partnership to boost investment in research on new treatments for PD, which affects 10 million people worldwide. Over the next three years, the Parkinson’s Foundation will invest a minimum of $3 […] August 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Gate Neurosciences emerges from stealth to tackle CNS diseases Gate Neurosciences has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders. Gate Neurosciences, a U.S. biotech company, was founded in 2019 by a team of neuroscience industry veterans to address the need for more effective treatments for CNS disorders, and to overcome long-standing challenges […] August 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 23 Aug 2022 Company’s 3D microchip gives mechanistic insights into human brain A microchip that allows scientists to study the complexity of 3D cellular networks at unrivaled scale and precision has been added to 3Brain AG’s brain-on-chip portfolio. In collaboration with Swiss precision manufacturing experts, CSEM, 3Brain AG made the announcement today (August 22). The cell-electronic interface technology will also allow scientists to gain novel mechanistic insights […] August 23, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 180 Life Sciences announce enrollment of the first patient in frozen shoulder treatment trial The first patient has been enrolled on a clinical trial to evaluate anti-tumor necrosis factor for patients with early-stage, pain predominant frozen shoulder. 180 Life Sciences, a clinical-stage biotechnology company made the announcement yesterday (August 22). James Woody chief executive officer of 180 Life Sciences, said: “Recruiting the first patient for the trial of anti-TNF […] August 23, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Alume Biosciences progressing with fluorescence study in patients undergoing head and neck surgery Alume Biosciences, Inc. says the first patient has been dosed in a phase 3 pivotal study of ALM-488, a peptide-dye conjugate designed to highlight nerves with fluorescence in real time during surgery. “The successful initiation of this phase 3 pivotal study is another major milestone for Alume Biosciences. It marks the final phase of clinical […] August 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Constructive Bio launches with $15M seed investment to re-engineer biology A biotech company has launched in the UK after securing a deal that includes intellectual property re-engineering biology by creating new classes of enzymes, pharmaceuticals and biomaterials. Constructive Bio has completed a $15 million (€15 million) seed round and gained an exclusive license from the Medical Research Council to intellectual property (IP) developed by Professor […] August 23, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email